28 results
8-K
EX-99.1
OSA
ProSomnus, Inc.
26 Mar 24
ProSomnus Reports Record Fourth Quarter and Fiscal Year 2023 Financial Results
4:22pm
by $1.4 million decrease in stock-based compensation.
Research and development expenses totaled $1.4 million for the quarter ended December 31, 2023 … . Relative to the quarter ended June 30, 2023, the commencement of our expense reduction initiative, research and development expenses remained consistent
424B3
3smjtwl7094dzq3
15 Nov 23
Prospectus supplement
4:37pm
8-K
EX-99.1
ti1tithryymvyd5q
9 Nov 23
ProSomnus, the Leading Non-CPAP Obstructive Sleep Apnea Therapy, Reports Record Third Quarter 2023 Financial Results
4:35pm
424B3
f2ku 8c9sp
9 Aug 23
Prospectus supplement
6:01am
8-K
EX-99.1
fbu wl5idhdzcpq
3 Aug 23
ProSomnus Reports Record Second Quarter 2023 Top-Line Financial Results
8:09am
424B3
5vp96
6 Jun 23
Prospectus supplement
4:05pm
10-Q
uex6j9spe wq87d
12 May 23
Quarterly report
9:23pm
8-K
EX-99.1
lw3fgv
9 May 23
ProSomnus Reports First Quarter 2023 Financial Results
4:01pm
10-K
sz87d0o6a4fg 0kx5n
14 Apr 23
Annual report
4:22pm
8-K
EX-99.1
ehsfk1qver
30 Mar 23
ProSomnus Reports Fourth Quarter and Fiscal Year 2022 Financial Results
4:59pm